

Supplementary Table S1. Characteristics of subjects<sup>1</sup> and endometrial biopsies in the study

Serial no.	Subject ID	Age	Cycle day	Histology	Diagnosis	Final selection
<i>Group 1 (Control, No endometriosis)</i>						
1	4	24	24	MSE	NAD	Yes
2	10	27	24	MSE	NAD	Yes
3	14	30	20	MSE	NAD	Yes
4	20	31	30	AE	AEB, LM	No
5	22	34	20	MSE	NAD	Yes
6	23	36	20	MSE	NAD	Yes
7	26	37	20	AE	LM	No
8	28	29	26	DyRM	EP	No
9	30	37	22	MSE	NAD	Yes
10	37	33	22	MSE	EP	No
11	39	32	25	MSE	NAD	Yes
12	45	24	20	MSE	NAD	Yes
13	48	28	23	MSE	NAD	Yes

14	59	29	26	LSE	NAD	No
15	64	27	20	AE	LM	No
16	EM1	36	26	MSE	NAD	Yes
17	EM63	33	24	MSE	NAD	Yes

---

*Group 2 (Ovarian endometriosis, stage IV)*

1	72	36	18	MSE	NAD	Yes
2	75	32	20	MSE	NAD	Yes
3	78	28	20	MSE	NAD	Yes
4	86	31	20	MSE	NAD	Yes
5	011	30	24	MSE	NAD	Yes
6	0111	36	24	MSE	NAD	Yes
7	112	32	26	DyRM	AM	No
8	113	35	22	MSE	NAD	Yes
9	114	31	20	MSE	NAD	Yes
10	115	26	20	DyRM	AM	No
11	119	22	20	ESE	EP, LM	No
12	120	33	24	MSE	NAD	Yes

13	126	33	22	AE	AM	No
14	128	28	18	MSE	NAD	Yes
15	129	32	18	DyRM	AEB	No
16	130	24	20	DyRM	LM	No
17	131	26	18	AE	AM	No
18	134	32	26	MSE	NAD	Yes
19	135	35	22	MSE	NAD	Yes
20	137	28	25	MSE	NAD	Yes

---

<sup>1</sup>all subjects were recruited from Infertility clinic and had been suffering from primary infertility.

AE, atrophic endometrium; AEB, abnormal endometrial bleeding; AM, adenomyosis; DyRM, dysregulated maturation; EP, endometrial polyp; ESE, early secretory phase endometrium; LM, leiomyoma; LSE, late secretory phase endometrium; MSE, mid-secretory phase endometrium; NAD, no abnormality detected.

Supplementary Figure S1. Composite plate of representative photomicrographs at low magnification for ErbBs1-4 immunostaining in MSE obtained from both groups. Bar: 100  $\mu$ m.

